NPCE NeuroPace Medical: Long-Term Debt to Capital Coefficient

NeuroPace, Inc. (NPCE) develops innovative RNS neurostimulators to combat severe forms of epilepsy, leveraging advancements in AI monitoring and the expansion of insurance coverage. This chart illustrates a metric of 5.65, while the company strengthens its leadership position in neurostimulation through deep learning. The brand is currently scaling adaptive therapy, offering mature technological solutions to improve patients' quality of life.

This indicator measures the proportion of long-term liabilities relative to equity, determining the degree of financial stability and bankruptcy risks associated with excessive borrowing. By analyzing the current level of long-term financial dependence, an investor can assess the reliability of the capital structure of NeuroPace, Inc. (NPCE), which is supported by high business macro-stability driven by guaranteed insurance payments for life-critical neurostimulators.